|Articles|October 1, 2002

Pharmaceutical Executive

  • Pharmaceutical Executive-10-01-2002

Tiered Pharmacy Benefit Plans on the Rise

In an effort to cope with soaring healthcare costs, more employers are establishing three-tier prescription drug benefit plans for workers.

In an effort to cope with soaring healthcare costs, more employers are establishing three-tier prescription drug benefit plans for workers. This year, almost 60 percent of workers with health insurance have pharmacy coverage that sets higher cost-sharing formulas for non-preferred medicines, compared with preferred products or generics. That figure is up considerably from the 36 percent of three-tiered plans in 2001 and is double the 29 percent rate in 2000. (See "More Workers Pay More.") The cost of pharmaceuticals within these tiers is also higher: brand-name therapies for which generic substitutes are available now cost consumers an average $26 co-pay per prescription, up from $20 in 2001, according to an annual survey of employer benefit plans conducted by the Kaiser Family Foundation (KFF) and the Health Research and Educational Trust (HRET). A total of 85 percent of workers now are in either two- or three-tiered plans, as more employers take steps to keep prescription drug costs under control.

More Workers Pay More

Articles in this issue

about 24 years ago

European Pricing Squeeze

about 24 years ago

FDA Shakes Things Up

about 24 years ago

The Patient's Lament

about 24 years ago

Rx Coverage Affects DTC Ad Impact

about 24 years ago

Merck Stays in Stride

about 24 years ago

A Fine Line

about 24 years ago

Under Investigation

about 24 years ago

Toward a Bigger Biotech

about 24 years ago

The Push for Generics

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.